Using Apolipoprotein B to Manage Dyslipidemic Patients: Time for a Change?
- 1 May 2010
- journal article
- editorial
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 85 (5) , 440-445
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best PracticesClinical Chemistry, 2009
- Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary SyndromesArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practiceJournal of Clinical Lipidology, 2008
- Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in ChineseJournal of Lipid Research, 2007
- Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study)The American Journal of Cardiology, 2007
- A Population-Based, Cross-Sectional Comparison of Lipid-Related Indexes for Symptoms of Atherosclerotic DiseaseThe American Journal of Cardiology, 2006
- Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) IIAmerican Heart Journal, 2006
- The Forgotten MajorityJACC, 2005
- Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) TrialCirculation, 2002
- Apolipoprotein Concentrations During Treatment and Recurrent Coronary Artery Disease EventsArteriosclerosis, Thrombosis, and Vascular Biology, 2000